Activation of Proteinase-Activated Receptor-2 by Human Kallikrein-Related Peptidases  by Stefansson, Kristina et al.
Activation of Proteinase-Activated Receptor-2
by Human Kallikrein-Related Peptidases
Kristina Stefansson1, Maria Brattsand1, Dirk Roosterman2, Cordula Kempkes2, Georgeta Bocheva2,
Martin Steinhoff2 and Torbjo¨rn Egelrud1
Proteinase-activated receptor-2 (PAR2) is a seven transmembrane spanning, G-protein-coupled receptor, present
on the membrane of many cell types including keratinocytes. In skin, PAR2 is suggested to play a regulatory role
during inflammation, epidermal barrier function, and pruritus. PAR2 is activated by trypsin-like proteases by a
unique mechanism where cleavage of the receptor leads to the release of a small peptide, which activates the
receptor as a tethered ligand. The endogenous activators of PAR2 on keratinocytes have not been identified as
of yet. Potential candidates are kallikrein-related peptidases (KLKs) expressed by epidermal cells. Therefore, the
ability of four human skin-derived KLKs was examined with regard to their capacity to activate PAR2 in vitro. PAR2
cleavage was followed by immunofluorescence analysis and functional activation by measurements of changes
in intracellular calcium levels. We found that KLK5 and KLK14, but neither KLK7 nor KLK8, induced PAR2
signalling. We conclude that certain, but not all, epidermal KLKs are capable of activating PAR2. We could also
show the coexpression of KLK14 and PAR2 receptor in inflammatory skin disorders. These in vitro results
suggest that KLKs may take part in PAR2 activation in the epidermis and thereby in PAR2-mediated inflammatory
responses, including epidermal barrier repair and pruritus. The role of KLKs in PAR2 activation in vivo remains to
be elucidated.
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INTRODUCTION
The skin forms a protective barrier not only by means of
constituting an efficient physico-chemical barrier but also via
its highly active and specialized participation in immune and
inflammatory reactions. The major cellular constituent of the
epidermis, the keratinocyte, has been described as a
‘‘cytokine factory’’ and plays an important role in our immune
defence (reviewed by Steinhoff et al., 2001). A new concept in
skin immunology is that proteolytic enzymes may act as key
modulators of biological functions in a cytokine-like manner.
Endogenous or exogenous proteinases may influence cells
through the activation of proteinase-activated receptors (PARs)
(reviewed by Steinhoff et al., 2005).
Proteinase-activated receptor-2 (PAR2) is a member of the
PAR family, which encompasses four PARs, designated PAR1–4
(Vu et al., 1991; Nystedt et al., 1995; Ishihara et al., 1997; Xu
et al., 1998). These are G-protein-coupled receptors with seven
transmembrane domains, which are activated by a unique
mechanism dependent on proteolytic cleavage. Upon cleavage
within the N-terminal extracellular part of the receptor, a
peptide is released that binds to and irreversibly activates the
receptor while still tethered to it. Activation leads to interaction
with heterotrimeric G-proteins in the plasma membrane and
downstream signalling events. Proteinases capable of activat-
ing PARs belong to the serine protease family and include
thrombin, trypsin, and cathepsin G. PAR2 is not activated by
thrombin but has been shown to be activated by the following
proteases in vitro: trypsin, mast cell tryptase, factor Xa, acrosin,
gingipain, and neuronal serine proteases (reviewed by Dery
et al., 1998; Macfarlane et al., 2001; Ossovskaya and Bunnett,
2004; Steinhoff et al., 2005). PAR2 is expressed by keratino-
cytes (Santulli et al., 1995; D’Andrea et al., 1998; Steinhoff
et al., 1999) where it may function as a regulator of growth and
differentiation (Derian et al., 1997) and is highly implicated in
inflammatory reactions (Steinhoff et al., 2005). Recently, PAR2
was identified as a novel signalling mechanism of the
epidermal permeability barrier (Hachem et al., 2006). The
endogenous activator of PAR2 in the epidermis, however, has
not been identified yet. It has been suggested that mast cell
tryptase may activate PAR2 during inflammatory conditions
upon mast cell infiltration and degranulation (Steinhoff et al.,
1999). Other possibilities include endogenous trypsin-like
proteases present in the epidermis.
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We have previously purified, cloned, and characterized
three epidermal serine proteases; human kallikrein-related
peptidase (KLK) 5 (hK5, stratum corneum tryptic enzyme,
SCTE), KLK7 (hK7, stratum corneum chymotryptic enzyme,
SCCE), and KLK14 (hK14) (Hansson et al., 1994; Brattsand
and Egelrud, 1999; Brattsand et al., 2005; Stefansson et al.,
2006). KLK8 is another human KLK, which is abundantly
present in the stratum corneum (Komatsu et al., 2005a).
These four enzymes all belong to the human kallikrein gene
family of 15 related serine proteases (Clements et al., 2001;
Yousef and Diamandis, 2001) and have different substrate
specificities. KLK5 and KLK8 have trypsin-like activity
(Brattsand et al., 2005; Rajapakse et al., 2005), whereas
KLK7 has chymotrypsin-like activity (Skytt et al., 1995).
KLK14 has mainly trypsin-like but also a significant chymo-
trypsin-like activity (Brattsand et al., 2005; Felber et al.,
2005). These enzymes are here denoted as human kallikrein-
related peptidases according to the new nomenclature
proposed by Lundwall et al. (2006).
Given the presence of both PAR2 and KLKs in the
epidermis, it is plausible that one or several KLKs may
function as activators of PAR2 and thus play a role in
inflammatory skin diseases. In this work, we investigated
whether KLKs 5, 7, 8, or 14 may be capable of activating
PAR2 in vitro. We selected KLKs 5, 7, and 14 because these
enzymes are known to be present in the skin in catalytically
active form (Egelrud, 1993; Brattsand and Egelrud, 1999;
Stefansson et al., 2006). KLK8 may, besides KLK11, be the
most abundant trypsin-like KLK in normal human skin
(Komatsu et al., 2005a). We show that KLK5 and KLK14,
but neither KLK7 nor KLK8, could activate PAR2. We also
show the colocalization of KLK14 and PAR2 in the epidermis
of inflammatory skin disorders. Thus, certain but not all KLKs
expressed by keratinocytes are potential endogenous activa-
tors of PAR2 within the epidermis, and may play a role in
epidermal barrier physiology/pathophysiology and itching.
RESULTS
Production and activation of recombinant KLKs
Production of active KLK5 and KLK14 has been published
elsewhere (Brattsand et al., 2005). Purified recombinant
proEK-KLK7 could, as expected, be activated by recombinant
enterokinase (rEK). Recombinant pro-KLK8, having the native
propeptide sequence, was also easily activated by rEK.
Activation was verified by a mobility shift on SDS-PAGE
(Figure 1) and by measuring activity toward chromogenic
peptide substrates. Active KLK8 fusion protein had an
apparent molecular mass of 38.6 kDa according to SDS-
PAGE analysis (Figure 1). Active-site titration of enzyme
preparations showed that around 30% (KLK7EK) and 60%
(KLK5EK) of the respective enzyme was active when
compared with expected activity according to protein
concentration determined with the DC Protein Assay. Close
to 100% of the KLK14 preparation was in active form. In
Figures 2 and 3, all KLK8 was assumed to be in active form.
However, as KLK8 does not react with a1-antitrypsin, it was
not possible to perform active-site titration of the enzyme in
the same way as for KLKs 5, 7, and 14, but taking into
account the proportion of active enzyme in the other
preparations, and the fact that electrophoretic analyses
showed no or negligible degradation of KLK8 (Figure 1), an
assumption was made that at least 30% of the KLK8
preparation should be functional. The active KLK8 prepara-
tion also showed high activity toward chromogenic peptide
substrates (see below).
Effects of KLKs 5, 7, 8, and 14 on Ca2þ mobilization
Trypsin, KLK5EK, and KLK14 stimulated Ca2þ mobilization in
Kirsten Murine Sarcoma Virus transformed rat kidney
epithelial (KNRK)-PAR2 cells (Figure 2a, b, and e), interpreted
as PAR2 signalling. No reaction was obtained when KLK7
EK
or KLK8, in concentrations from 0.1 nM up to 10 mM, was used
(Figure 2c and d). However, subsequent addition of 100 nM
trypsin to the same cells gave an expected reaction,
confirming the integrity of cells (Figure 2c and d). Addition
of rEK in concentrations similar or higher to that present in
preparations of KLK5EK, KLK7EK, and KLK8 did not lead to any
detectable Ca2þ mobilization (data not shown). Figure 3a
shows dose response curves. Both trypsin and KLK14 were far
more potent activators of PAR2 than KLK5
EK. The lowest
detectable signal was obtained at 50 nM concentration for
KLK14. KLK5EK gave a detectable signal at 0.1 mM. Even at
1 mM, the signal obtained with KLK5 was lower than that for
KLK14 at 50 nM. Neither KLK7 nor KLK8 could activate PAR2.
The ability of KLK5 and KLK14 to induce Ca2þ mobilization
in cells via the PAR2 signal system was confirmed using
human dermal microvascular endothelial cells naturally
expressing functional PAR2 receptors (Figure 3b; Shpacovitch
et al., 2002).
Immunofluorescence analyses
By using antibodies to the Flag and the HA11 epitopes of the
PAR2 receptor, we were able to discriminate between intact
and cleaved PAR2. The antibody to the extracellular Flag
would detect only uncleaved receptor, because proteolytic
cleavage removes the proximal Flag epitope. Results from
immunofluorescence analyses (Figure 4) were in accordance
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Figure 1. Preparations of recombinant human tissue KLK protein precursors
and active enzymes. Coomassie brilliant blue stained SDS-PAGE.
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with the results obtained in Ca2þ mobilization assays. After
treatment with 1 mM recombinant KLK5EK or KLK14, no
staining of the Flag epitope could be detected around the
cell membrane, indicating cleavage and loss of the extra-
cellular part of the PAR2 receptor. Treatment with 1 mM
KLK7EK or KLK8 did not abolish staining of the Flag epitope,
that is, with these enzymes results similar to the negative
control with cells treated with vehicle only were obtained.
rEK treatment did not have any effect on immunofluores-
cence patterns (results not shown).
Kinetic properties of KLK8
Despite its trypsin-like properties, KLK8 did not give any
detectable PAR2 activation. Therefore, we wanted to test this
enzyme against a series of chromogenic peptide substrates
and compare its kinetic properties to that of KLK14. The
results with the chromogenic peptide substrates S-2251,
S-2288, and S-2302 (see Materials and Methods for struc-
tures) are shown in Table 1. KLK8 had a catalytic rate (kcat)
and catalytic efficiency (kcat/Km) 3–5 times lower than that of
KLK14 for S-2288 and S-2302. Whereas S-2251 was readily
cleaved by KLK8, it was not cleaved at detectable rates by
KLK14.
Immunolocalization of KLK14 and PAR2 in inflammatory skin
disorders
Staining of inflamed skin from patients with atopic dermatitis
and rosacea shows immunoreactivity of both KLK14 and
PAR2 widely distributed in the upper squamous and granular
layers (Figure 5).
DISCUSSION
PAR2 has been implicated in immunological and inflamma-
tory responses of many tissues. This receptor may contribute
to the pathophysiology of inflammatory skin diseases such as
atopic dermatitis and psoriasis (Steinhoff et al., 1999, 2005).
It has also been depicted as a novel pathway for pruritus in
human skin (Steinhoff et al., 2003) and for events linked to
lamellar body secretion in response to epidermal barrier
injuries (Hachem et al., 2006). The nature of the proteinases
which activate PAR2 in the skin under physiological and
pathophysiological conditions is, however, still uncertain.
Therefore, the aim of this study was to identify possible
endogenous activators of PAR2 in the epidermis. Candidates
were four serine proteinases within the family of KLKs.
Several KLKs have been shown to be produced by epidermal
cells (Sondell et al., 1994; Brattsand and Egelrud, 1999;
Komatsu et al., 2003, 2005a, b; Stefansson et al., 2006). In
this work, we focused on KLKs 5, 7, 8, and 14. So far,
epidermal KLKs 5 and 7 have been predominantly implicated
in the process of desquamation (Egelrud and Lundstro¨m,
1991; Lundstro¨m and Egelrud, 1991; Egelrud, 1993; Ekholm
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Figure 2. Ca2þ responses to trypsin and KLK in KNRK-PAR2 cells.
KNRK-PAR2 cells were treated with (a) 1 mM trypsin (T), (b) 10mM KLK5
EK,
(c) 10mM KLK7EK, (d) 10 mM KLK8, and (e) 1 mM KLK14. Trypsin or KLK was
added at indicated time points (arrows). If no response could be detected,
the integrity of the cells was verified by addition of 100 nM trypsin (T).
100
75
50
1
225
%
 C
a2
+
0
–12 –11
log M
–10
*
*
–9 –8 –7 –6
100
75
50
25
%
 C
a2
+
0
–12 –11
log M
–10 –9 –8 –7 –6
Figure 3. Dose response curves for Ca2þ mobilization in response to trypsin
and KLK. (a) KNRK-PAR2 cells were treated with active trypsin (circles),
KLK5EK (triangles), KLK7EK (crosses), KLK8 (diamonds) or KLK14 (squares).
Means7SEM, nX3 for trypsin, KLK5EK, and KLK14. For KLK7EK and KLK8,
experiments were carried out in duplicate at 1 mM, at lower concentrations
single experiments were performed. *1: statistically significantly different
from baseline (n¼ 3, P¼ 0.04); *2: statistically significantly different from
baseline (n¼4, P¼ 0.003). (b) Human dermal microvascular endothelial cells
(hDMEC) cells were treated with active trypsin (circles), KLK5EK (triangles), or
KLK14 (squares) with concentrations as indicated in the figure. 100% Ca2þ
corresponds to fluorescence ratio 340/380 nm¼ 2.
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et al., 2000; Caubet et al., 2004). However, similar as PAR2,
both KLKs 5 and 7 show the highest expression in the stratum
granulosum, suggesting a possible interaction between these
proteinases and PAR2 (Sondell et al., 1994; Steinhoff et al.,
1999; Ekholm et al 2000). In this context, also KLK14 may be
of interest. In normal skin, the highest expression of this
enzyme is seen in sweat ducts (Stefansson et al., 2006). It
exhibits trypsin-like specificity and a high catalytic efficiency
(Brattsand et al., 2005). Thus, KLK14 may also be associated
with PAR2 activation via a paracrine mechanism. KLK8,
another trypsin-like KLK (Rajapakse et al., 2005), is abun-
dantly present in the stratum corneum (Komatsu et al., 2005a)
and may therefore also be a possible activator of PAR2 in the
epidermis.
In the dermis, a likely activator of PAR2 is mast cell
tryptase. Steinhoff et al. (1999) showed that tryptase stimu-
lated a rapid increase of intracellular calcium concentration in
cultured human keratinocytes. Mast cell tryptase may
constitute as much as 20% of the total protein content of
mast cells. Under inflammatory conditions such as atopic
dermatitis, the number of mast cells in the dermis is
dramatically increased, and mast cells can be found close to
the dermal–epidermal border. Also in psoriasis, there is an
increased number of dermal mast cells, sometimes apparently
invading the epidermis (Steinhoff et al., 1999). Considering
the fact that keratinocytes in high suprabasal epidermal layers
show the highest expression of PAR2 under normal conditions
(Steinhoff et al., 1999), it seems less likely, however, that
tryptase would be the only PAR2-activating enzyme in the
skin. Besides mast cell tryptase, another possible activator of
PAR2 in the epidermis is trypsin IV (Cottrell et al., 2004).
Trypsin IV generated by keratinocytes in human skin can
Table 1. Kinetic parameters of recombinant human KLK8 and KLK14
Enzyme Substrate Enzyme concentration (nM) Km (mM) Vmax
1 (nMs1) kcat
1 (s1) kcat/Km (s
1
M
1)
KLK82 S-2251 50 0.37 99 2.0 5.3 103
S-2288 50 0.16 160 3.2 2.0 104
S-2302 50 0.13 100 2.1 1.7 104
KLK142 S-2251 50 — — — —
S-2288 10 0.18 120 12 7.0 104
S-2302 10 0.081 61 6.1 7.5 104
kcat, catalytic rate; kcat/Km, catalytic efficiency; KLK, human kallikrein-related peptidase.
1Values for Km and Vmax represents means from four different experiments.
2For KLK8, all enzyme protein was assumed to be catalytically active; the concentration of KLK14 was calculated from active-site titration.
‘‘—’’, no enzyme activity could be detected.
PAR2-Flag PAR2-HA11 Merged
KLK5EK
KLK7EK
KLK8
KLK14
Trypsin
Negative
control
PAR2-Flag PAR2-HA11 Merged
10 m
Figure 4. Confocal photomicrographs of KNRK-PAR2 cells stimulated with trypsin or KLK. KNRK-PAR2 cells were stimulated with KLK5
EK, KLK7EK,
KLK8, KLK14, or trypsin, all at 1 mM. Negative control shows cells incubated in DMEM/0.1% BSA only. Cells incubated with rEK looked like cells in negative
control (data not shown). Cells were stained with anti-Flag antibody toward extracellular Flag epitope and anti-HA antibody toward intracellular HA11 epitope.
Merged: superimposition of images in the same row. Yellow color in superimposed images indicates no degradation of extracellular parts of PAR2.
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activate PAR2 in vitro (M Steinhoff, unpublished observation).
Cottrell et al. (2004) showed that trypsin IV is able to activate
PAR2 in KNRK-PAR2 cells as well as in the epithelial cell lines
PC-3 (prostate) and SW480 (colon). These results were,
however, questioned by Grishina et al. (2005), who claimed
that trypsin IV cannot activate PAR2 in epithelial cells. The
opposing results may be due to different glycosylation or
transactivation mechanisms (Hollenberg and Compton, 2002).
In normal skin, PAR2 is highly expressed by keratinocytes.
The highest levels can be found in the stratum granulosum.
PAR2 is also localized in keratinocytes of hair follicles and
sebaceous glands, as well as endothelial cells, myoepithelial
cells of sweat glands, and dermal dendritic cells (Steinhoff
et al., 1999). Under inflammatory conditions, staining for
PAR2 can also be observed in primary afferent nerve fibers
(Steinhoff et al., 2000, 2003). In atopic dermatitis, differing
from normal conditions and psoriasis, PAR2 is expressed also
by keratinocytes in lower epidermal layers (Steinhoff et al.,
1999, 2003). In this work, we show that KLK14 and the PAR2
receptor are coexpressed in the upper squamous and granular
layers of inflammatory skin (Figure 5).
We found that KLK5 and KLK14, but not KLK7 nor KLK8,
were able to activate PAR2. The positive results of KLK5 and
KLK14 were confirmed in a recent study of Oikonomopoulou
et al. (2006), where they also found that KLK6 could activate
PAR2. Owing to its chymotrypsin-like primary substrate
specificity (Skytt et al., 1995), the inability of KLK7 to
activate PAR2 was expected. Trypsin-like KLKs show different
substrate specificities, which may reflect different functions
among these enzymes in the skin. Considering the trypsin-
like primary substrate specificity of KLK8 (Rajapakse et al.,
2005), its abundance in the stratum corneum (Komatsu et al.,
2005a) and the capacity of KLKs 5 and 14 to activate PAR2,
the inability of KLK8 to activate PAR2 was unexpected. In
order to confirm that our KLK8 preparation was active, we
compared the catalytic properties of KLKs 8 and 14. We
found that KLK8 had a catalytic efficiency 3–6 times lower
than KLK14 against the chromogenic substrates S-2288 and
S-2302. On the other hand, KLK8 was able to cleave S-2251,
a substrate not cleaved by KLK14 (Table 1). Hence, KLK8
is active but differs in its substrate specificity from KLK14.
This difference may be reflected in the inability of KLK8 to
activate PAR2. A functional difference among KLKs in the skin
is supported also by the fact that KLK5, which has a catalytic
efficiency around 100-times lower than KLK14 toward
S-2288 (Brattsand et al., 2005), could activate PAR2. In
this context, it should be noted that an inactivation of PAR2
by KLK7 and KLK8 could be ruled out by control experiments
(cf. Figure 2c and d).
PAR2 activation in the skin may be involved in the
elicitation of itch. PAR2 as well as tryptase has been shown to
be highly expressed in lesional skin in atopic dermatitis
(Steinhoff et al., 2003 and Figure 5). Neuronal PAR2 can be
activated by tryptase (Steinhoff et al., 2000), and PAR2
agonists induce pruritus in atopic dermatitis. It has therefore
been suggested that PAR2 activation may play a major role in
pruritus of atopic dermatitis (Steinhoff et al., 2003). The
presence of KLKs in sweat, and the fact that sweating is the
most common itch-triggering factor in atopic dermatitis, may
be of relevance in this context. Komatsu et al. (2006) showed
that among other KLKs, KLKs 5, 7, 8, and 14 are present in
sweat. We have earlier found that KLK14 is preferentially
detected in sweat ducts and glands by immunohistochemistry
of normal skin (Stefansson et al., 2006). Although the
concentration of KLK14 may be low in sweat (Komatsu
et al., 2006), its high catalytic efficiency (Brattsand et al.,
2005) and its ability to activate PAR2 could make this
protease (together with other proteases) an important sweat-
mediated itch inducer. It may be speculated that skin barrier
defects in atopic dermatitis (Werner and Lindberg, 1985;
Linde, 1992) may provide access to pruritogenic nerve fibers
for sweat-carried KLKs such as KLK14. Proteinases, as itch
mediators, have been proposed for a long time (reviewed by
Sta¨nder and Steinhoff, 2002; Steinhoff et al., 2006).
In conclusion, we clearly demonstrated that at least two
(but not all) KLKs present in human epidermis can act as PAR2
Atopic dermatitis
KLK14 KLK14
KLK14KLK14
Negative control Negative control
PAR2 PAR2
Rosacea
a e
fb
c g
hd
Figure 5. Immunoreactivity of KLK14 and PAR2 in inflamed skin tissues.
Immunoreactivity of KLK14 as well as PAR2 was found widely distributed in
the upper squamous and granular layer in patients with inflammatory skin
disorders. (a–d) Atopic dermatitis, (e–h) rosacea. Staining was performed with
antisera specific for (a, b, e, f) KLK14 or (c, g) PAR2. (d, h) Negative controls.
Inset size bars¼50 mM (b, f) or 100 mM.
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activators in vitro. The situation in vivo remains to be
elucidated. Our results give further evidence that epidermal
proteases may play important roles not only under normal
conditions but also under pathophysiological conditions
including skin inflammation, epidermal barrier function,
and pruritus.
MATERIALS AND METHODS
All described studies were approved by the medical ethical
committee of Umea˚ University and performed according to the
Declaration of Helsinki Principles. All participants gave their written
informed consent.
Cell lines
KNRK cells stably expressing human PAR2 with N-terminal Flag
epitope and C-terminal HA11 epitope (Bohm et al., 1996; Dery
et al., 1999; DeFea et al., 2000) were propagated in DMEM high
glucose (Invitrogen, Groningen, The Netherlands), 10% bovine calf
serum, 200mg/ml geneticin (G-418) (Invitrogen, 10131). For passage
of cells, cell dissociation buffer enzyme-free Hank’s-based (Invitro-
gen, 13150-016) was used. Human dermal microvascular endothe-
lial cells, derived from dermis at the proliferating state, expressing
functional PAR2 receptors were grown in Endothelial Cell Basal
Medium (PromoCell, Heidelberg, Germany), as described (Shpa-
covitch et al., 2002).
Production and activation of recombinant proteins
KLK5EK was produced as proEK-KLK5 in High Five insect cells and
activated as described by Brattsand et al. (2005). KLK14 was
produced in active form in Pichia pastoris KM71H as described by
Brattsand et al. (2005).
Active KLK7EK was produced by enterokinase treatment of pro-
KLK7 with the activation site replaced by an enterokinase cleavage
site (Huang et al., 1997), proEK-KLK7. ProEK-KLK7 was produced by
site-directed mutagenesis, using the Quick-Change Site-Directed
Mutagenesis kit (Stratagene, La Jolla, CA) with pS500 plasmid
as template (Hansson et al., 1994), and the primer pair KLK7EKs
(50-CTGCAGGAGAAGAAGCCGATGATGACAAGATTATTGATGG
CGCC-30) and KLK7EKas (50-GGCGCCATCAATAATCTTGTCATCAT
CGGCTTCTTCTCCTGCAG-30). As this rendered an incomplete
activation site (DDDK), one additional D was inserted through
amplification with primers KLK7FD4K (50-GAAGAAGACGATGAT
GACAAGATTA-30) and KLK7R2 (50-TCTAGATTAGCGATGCTTTTTC
ATGGTGTCAT-30). The reverse primer included a stop codon and an
Xba1 site. The resulting fragment was cloned into a TOPO TA vector
(Invitrogen) and then transferred into the pPICZaA vector through
cleavage with restriction enzymes EcoR1 and Xba1 and subsequent
ligation. P. pastoris strain X-33 was transformed with the pPICZaA-
KLK7EK vector using the Easy Comp Transformation kit (Invitrogen).
Recombinant protein was produced essentially as described in the
EasySelect Pichia Expression Kit manual, purified, and activated as
described for KLK5 and KLK14 by Brattsand et al. (2005). ProEK-KLK7
activation was performed by incubation with 0.006 U of rEK per mg
recombinant proenzyme for 5 hours at room temperature (RT) under
conditions as described (Brattsand et al., 2005).
(cDNA)KLK8 was cloned from total RNA prepared from human
epidermis (Brattsand and Egelrud, 1999), using the primer pair
KLK8F1 (50-CAGGAGGACAAGGTGCTGGGG-30) and KLK8R1
(50-CCCTTGCTGATGATCTTCTTG-30). (cDNA)KLK8 fragment was
ligated into a TOPO TA vector and thereafter transferred into the
pPICZaA vector. The construct was used to transform P. pastoris
strain KM71H using the Easy Comp Transformation kit. Recombinant
protein was produced according to manual. As the reverse primer
does not contain a stop codon, this results in a protein containing
C-terminal His- and V5 tags. Purification of pro-KLK8 was made in
several steps. First, conditioned cell media were concentrated by
precipitation with 80% saturated ammonium sulfate. The pellet was
dissolved in 1/10 of the original volume in 20 mM Tris-HCl pH 8.0.
The mixture was filtered through a 0.45 mM Millipore filter and then
subjected to reversed phase chromatography. The first chromato-
graphy step was followed by ion exchange chromatography and a
second run of reversed phase chromatography (Brattsand and
Egelrud, 1999). Recombinant pro-KLK8 was activated by incubation
with rEK, 0.02 U per mg protein as described for proEK-KLK5 by
Brattsand et al. (2005).
Accuracy of desired nucleotide sequences was verified by
sequencing using the Big Dye Terminator Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) and analyzed using an ABI377
automated DNA sequencer (Applied Biosystems). The sequence of
(cDNA)KLK8 was compared and matched to the published sequence
of KLK8 transcript variant 1 (accession no. NM_007196). The
sequence of (cDNA)KLK7EK was compared to the published
sequence of KLK7 transcript variant 1 (GenBank NM_005046).
Protein concentration was determined with the DC Protein Assay
(Bio-Rad Laboratories, Hercules, CA). All active protein preparations
used, with the exception of KLK8, were active-site titrated with a1-
antitrypsin (Sigma, St Louis, MO, A-9024), essentially according to
Salvesen and Nagase (1994). Known amounts of bovine pancreatic
trypsin (Sigma, T-8253) were used for standardization.
Measurement of intracellular calcium concentration
PAR2 signalling was assessed by measuring cytosolic [Ca
2þ ] with
fura 2-AM (Molecular Probes, Eugene, OR, F-1201) (Bohm et al.,
1996; Dery et al., 1999; DeFea et al., 2000). Cells growing on glass
coverslips were loaded with 2.5 mM fura 2-AM in Hank’s buffer/0.1%
BSA (PAA Laboratories GmbH, Co¨lbe, Germany, Fraction V K41-
001-100) at 371C for minimum 25 minutes. Extracellular fura 2-AM
was removed by rinsing in Hank’s buffer/0.1% BSA. Cells were
transferred to a cuvette with 371C Hank’s buffer/0.1% BSA and
placed in a spectrofluorometer (Fluoro-Max2, Yobin Yvon GmbH,
Munich, Germany). Cells were challenged with recombinant KLK or
trypsin (Sigma, T-4665) at 0.1 nM to 10 mM concentrations. Fluore-
scence was measured at 340 and 380 nm excitation wavelengths.
The ratio of the fluorescence signal at the two wavelengths, which is
proportional to the intracellular calcium ion concentration, was
calculated.
Immunofluorescence and confocal microscopy
Cells were grown on glass coverslips in DMEM until near
confluence. The coverslips were transferred into an incubation
chamber and washed once with DMEM/0.1% BSA preheated to
371C. Cells were incubated with 1mM recombinant KLK or trypsin
(Sigma, T-4665), diluted in DMEM/0.1% BSA for 10 minutes at 371C.
Negative controls were treated with rEK in amounts corresponding to
rEK content in activated enzyme preparations or appropriate buffer
only. Cells were fixed with ice-cold methanol for 20 minutes on ice.
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Cells were washed and subsequently treated with 0.3% Triton-X 100
in phosphate-buffered saline (PBS)/0.1% BSA for 15 minutes. The
cells were washed before blocking in blocking solution (PBS/2%
goat serum (DakoCytomation, Glostrup, Denmark, X0907)) for
60 minutes at RT. Cells were incubated with mouse anti-Flag M1
mAb (Sigma, F 3040) diluted 1:200 and rabbit anti-HA antibody
(Sigma, H 6908) diluted 1:200 over night at 41C. After washing in
blocking solution, cells were incubated with secondary antibodies:
FITC-conjugated AffiniPure goat anti-rabbit antibody (Jackson
Immuno Research, Cambridgeshire, UK, 111-095-003) and Cy3
AffiniPure anti-mouse antibody (Jackson Immuno Research, 715-
166-151) diluted 1:200 in blocking solution, for 4 hours in the dark
at RT. The cells were again washed and mounted on superfrost slides
using Vectashield mounting medium (Vector Laboratories, Burlin-
game, CA, H-1000). Specimens were observed using a Bio-Rad MRC
1.000 confocal microscope. Images were collected at 0.68 mM
intervals using a Zeiss *100 Plan Apo 1.4 NA objective and a zoom
from 1.5–2 X.
Enzyme kinetics
Buffer (37.5 mM Tris-HCl pH 8.0/0.1 M NaCl/0.0075% Tween-20),
enzymes (final concentrations as specified in Table 1), and
chromogenic peptide substrates (Haemochrom Diagnostica AB,
Mo¨lndal, Sweden) at final concentrations ranging from 50 to
900mM (S-2251 (H-D-Val-Leu-Lys-pNA 2HCl), S-2302 (H-D-Pro-
Phe-Arg-pNA 2HCl)) or 1,000 mM (S-2288 (H-D-Ile-Pro-Arg-
pNA 2HCl)) were mixed in a 96-well plate. Total volume in each
well was 77.5 ml. Mixtures were incubated in duplicate at RT for
10 minutes in an ELISA reader (SpectraMAX 340, Molecular Devices,
Berkshire, UK). The apparatus was calibrated using known amounts
of pNA (Haemochrom Diagnostica AB). Km and Vmax values were
calculated using a Lineweaver Burk plot. rEK in amounts corre-
sponding to that used for activation of KLK8 gave no detectable
activity toward any of the substrates used.
Immunohistochemistry
Tissues were fixed in 10% (w/v) buffered formalin and embedded in
paraffin. Slides (5–6 mm) were cut and incubated for 30 minutes at
601C. Afterwards, sections were dewaxed, rehydrated, and heated in
a steamer (MultiGourmet plus FS20, Braun, Kronberg, Germany) for
25 minutes in 0.1 M ChemMate Target Retrieval Solution (Dako-
Cytomation) in a plastic cuvette. Sections were allowed to cool in
this buffer for 20 minutes. Endogenous peroxidase activity was
quenched with 100 mM NaN3/0.1% (w/v) H2O2 in PBS for
20 minutes at RT. After washing with PBS, sections were blocked
with 2% (w/v) BSA in PBS for 25 minutes at RT. Sections were
incubated with first specific polyclonal antibody diluted in 1% (w/v)
BSA overnight at 41C in a humid chamber. For KLK14, Em-14
(1.6 mg/ml; Stefansson et al., 2006) and for PAR2, H-99 at final
concentration 0.4mg/ml (Santa Cruz Biotechnology, Santa Cruz, CA)
was used. Negative controls were prepared by omission of the
primary antibodies. Specificity of Em-14 antibody to KLK14 has been
shown through adsorption experiments (Stefansson et al., 2006).
After rinsing with PBS, slides were incubated with secondary
antibodies for 1 hour at RT in a humid chamber (EnVisionþ System
Labeled Polymer-HRP, anti-rabbit; DakoCytomation). The immunor-
eactivity was detected with the Liquid DABþ Substrate Chromogen
System (DakoCytomation). Sections were counterstained with
Hematoxylin QS (Vector Laboratories) and mounted with Aqua-
mount (BDH, Poole, UK). Stainings were examined using a DM LB
microscope (Leica, Solms, Germany), equipped with a HV-C20M
CCD camera (Hitachi, Rodgau, Germany) and Diskus 4.20 software
(Carl H. Hilgers, Ko¨nigswinter, Germany).
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